definiens: shall mean, with respect to any [COMPANY] Product or ACADIA Product, the amount invoiced byAllergan or ACADIA, their Affiliates or sublicensees to Third Parties which are not Affiliates or sublicensees of theselling party, unless such Affiliates or sublicensees are the end users of such [COMPANY] Product or ACADIA Product inwhich case the amount billed therefor shall be deemed to be the amount that would be invoiced to a Third Party in anarm ’s length transaction, for the sale of such products less ( i ) cash discounts and/or quantity discounts allowed ; ( ii)credits and allowances of returns, rejections and recalls ; ( iii ) charges for freight, insurance and transportationspecifically included in the amount invoiced ; ( iv ) sales and use taxes, duties or other governmental tariffs and othersimilar taxes incurred and government mandated rebates, ( v ) accruals for estimated wholesaler chargebacks, contractrebates and bid rebates and Medicaid and other similar government mandated rebates as [COMPANY] or ACADIA may berequired to pay from time to time, all of which shall be determined in accordance with such party ’s standardaccounting methods . In the event an [COMPANY] Product or an ACADIA Product is sold in a combination product withother biologically active components, Net Sales, for purposes of royalty payments on the combination product, shallbe calculated by multiplying the Net Sales of that combination by the fraction A / B, where A is the gross selling priceof the [COMPANY] Product or ACADIA Product sold separately and B is the gross selling price of the combinationproduct . In the event that no such separate sales are made, Net Sales for royalty determination shall be calculated bymultiplying Net Sales of the combination by the fraction C/(C+D ), where C is the fully allocated cost of the activeingredient ( Collaboration Lead Compound ) in the [COMPANY] Product or ACADIA Product and D is the fully allocated costof such other biologically active components . In no event shall Net Sales of any * * * Certain confidential information on this page has been omitted and filed separately with the Commission